11月1日,医疗器械公司 NovoCure Limited (NVCR)股价在盘中出现大涨,股价最高上涨逾5%,引发市场广泛关注。分析人士指出,有望上调的业绩预期或是导致该股价飙升的主要原因。
作为一家专注于研发用于实体肿瘤癌症治疗的 TTFields 产品的公司,NovoCure 目前拥有 Optune Gio 和 Optune Lua 等主力产品线。最新财报显示,该公司实现营收 1.5 亿美元,虽然净利润出现亏损,但市场对其长期发展前景保持乐观。
业内人士分析称,随着 NovoCure 产品线在全球市场的持续扩张,其未来营收有望稳步增长,利润率也将逐步改善。部分机构预计,该公司明年或将会上调业绩指引,对股价形成支撑。不过具体影响还有待进一步观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.